Physician profile
Jack E Ebani
NPI 1962563932
$916.53
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $135 · 2021: $310 · 2022: $265.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $350.12 | 2019-2022 | |
| Pfizer INC. | $147.21 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.83 | 2019-2021 | |
| Janssen Biotech, INC. | $89.78 | 2019-2022 | |
| Myovant Sciences INC. | $39.14 | 2021-2022 | |
| Abbvie INC. | $38.02 | 2020-2021 | |
| Medtronic, INC. | $26.85 | 2021 | |
| Dendreon Pharmaceuticals LLC | $25.37 | 2021-2022 | |
| Boston Scientific Corporation | $22.89 | 2021 | |
| Mission Pharmacal Company | $16.19 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $14.62 | 2021 | |
| Merck Sharp & Dohme LLC | $14.60 | 2022 | |
| Urovant Sciences INC | $12.67 | 2021 | |
| Myriad Genetic Laboratories, INC. | $11.24 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Ebani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.